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Abstract. Molecular image-guided surgery has the potential for translating the tools of molecular pathology to
real-time guidance in surgery. As a whole, there are incredibly positive indicators of growth, including the first
United States Food and Drug Administration clearance of an enzyme-biosynthetic-activated probe for surgery
guidance, and a growing number of companies producing agents and imaging systems. The strengths and
opportunities must be continued but are hampered by important weaknesses and threats within the field.
A key issue to solve is the inability of macroscopic imaging tools to resolve microscopic biological disease
heterogeneity and the limitations in microscopic systems matching surgery workflow. A related issue is that
parsing out true molecular-specific uptake from simple-enhanced permeability and retention is hard and requires
extensive pathologic analysis or multiple in vivo tests, comparing fluorescence accumulation with standard histo-
pathology and immunohistochemistry. A related concern in the field is the over-reliance on a finite number of
chosen preclinical models, leading to early clinical translation when the probe might not be optimized for high
intertumor variation or intratumor heterogeneity. The ultimate potential may require multiple probes, as are used
in molecular pathology, and a combination with ultrahigh-resolution imaging and image recognition systems,
which capture the data at a finer granularity than is possible by the surgeon. Alternatively, one might choose
a more generalized approach by developing the tracer based on generic hallmarks of cancer to create a more
“one-size-fits-all” concept, similar to metabolic aberrations as exploited in fluorodeoxyglucose - positron emis-
sion tomography (FDG-PET) (i.e., Warburg effect) or tumor acidity. Finally, methods to approach the problem of
production cost minimization and regulatory approvals in a manner consistent with the potential revenue of the
field will be important. In this area, some solid steps have been demonstrated in the use of fluorescent labeling
commercial antibodies and separately in microdosing studies with small molecules. © The Authors. Published by SPIE under
a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original
publication, including its DOI. [DOI: 10.1117/1.JBO.23.10.100601]
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Molecular image-guided surgery has emerged as a very active
research field with transformative potential to allow surgeons to
see the molecular phenotype or even genotype of diseased and
normal tissues during surgery.1–5 Much of this field’s clinical
foundational roots have been developed based upon vascular
perfusion imaging with indocyanine green,6–8 with significant
growing interest in the use of other Food and Drug
Administration (USFDA)-approved agents, such as sodium
fluorescein, methylene blue, and isosulfan blue, which can have
different transport and localization kinetics.9–12 Also related
are the use of endogenous signals such as autofluorescence
attributed to NADH/FAD concentrations, as well as absorbers
such as hemoglobin and lipids13 and scattering agents, such
as endogenous14,15 or surface-enhanced Raman scattering.16
There have also been decades of studies and approvals in
photodynamic agents for diagnostic use in surgery, using
porphyrins, phthalocynanines, and chlorins as uptake markers
of tumors.17–23 A major milestone in this field just occurred,
which was the USFDA approval of aminolevulinic acid-induced
protoporphyrin IX to guide neurosurgery.24 Although already
used in Europe, this action represents the first biosynthetically
activated molecular probe approved for human use to guide
surgery in the United States (US), named Gleolan (NX Dev
Corp., recently acquired by photonamic GmbH & Co. KG).
While 5-aminolevulinic acid hydrochloride (ALA) has been
used in human research and approved for human use for
diagnostics for decades, this recent approval comes from the
result of a Phase III trial, is industry supported, and is indepen-
dent of the imaging system used. This combination of features
marks a very important turning point in the field. However,
as a field of research in the US, surgical guidance is highly
delocalized and broken down into subspecialties, without sig-
nificant intercommunication, even though there is a high level
of activity in each discipline. So, while many research groups
are poised to achieve major discoveries and seminal studies in
surgical trials, yet there is also some sense that there are major
barriers to seeing this happen. This review focuses on the key
aspects that require care in the clinical translation pipeline,
or aspects that may be limiting the field today, and some
major threats that could potentially stop the advancement of
the field if not solved.
Several key factors influencing the field are shown in
Table 1, broken down by analysis of strengths, weaknesses,*Address all correspondence to: Brian W. Pogue, E-mail: brian.w.pogue@
dartmouth.edu
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opportunities, and threats (SWOT paradigm). Many of the
strengths of the field have historically been described as
needs or opportunities, but at this time, there have been major
improvements that can now be counted as strengths of the field.
Each of the four areas is discussed in detail in the following
paragraphs.
Arguably, one of the most important strengths of the field
today is the commercial interest in providing imaging systems,
leading to prototypes with strong ergonomic features for clinical
use. The lack of choice and features in these systems has been a
problem in the past, but today there are many systems that have
been steadily improving. This success has largely been due to
resurgence in the use of indocyanine green (ICG) for tissue per-
fusion assessment, largely driven by Novadaq Tech. Inc. (now
acquired by Stryker Corp.) pushing the field forward to evolve
the commercial market for this type of direct visual guidance.25
This has enticed production of multiple systems from manufac-
turers with more differentiating features to the original systems
and adoption into many different surgical specialty systems.26
There is clearly concern about variation in system capabilities
and the potential confusion of systems, and this is a topic
of ongoing study in the technical performance, calibration,
references standards, professional consensus, and regulatory
guidance.26–30 This ongoing evolution and discussion at a
high level of technological activity should be viewed as a
strength of the field. However, much of the activity is based
on anticipated success in the development of companion diag-
nostic agents that are highly sensitive, nontoxic, and can fit into
the workflow of surgery. Similar strengths are in the early entry
into exploratory uses of ICG in Phase 0/1 trials in a number of
centers, as well as first in human studies of new molecules
(shown in Table 2).5
The key major opportunity for this field lies in the wide-
spread adoption of molecular pathology and proteomic/genomic
phenotyping of diseases in all major care centers.31 This
means that, currently, surgeons have more knowledge than
ever before about what the phenotype of the tissue is that
they will be operating on, and this field is growing at an explo-
sive rate. It is very likely that within the next decade that all
tumors will have full profiling from mRNA, DNA, or proteomic
assay. However, until this phenotypic profiling is truly used in
surgical guidance, it remains an undeveloped opportunity.
Still the idea of using the most specific proteins as carriers
of molecular probes to deliver them to target tissue is extremely
attractive. Particularly, the cancer therapeutics world has solid
progressive growth-targeted inhibitors or proteins that could
utilize a fluorescent companion diagnostic agent. The concept
of adopting therapeutic antibodies as the fluorophore-carrying
moiety,32 thereby using therapeutic biologicals as imaging
agents, has already been demonstrated in ongoing surgical
trials.33,34 Further growth along this direction is very likely
going to happen and will capitalize on this approach. The oppo-
site opportunity is also possible, that molecular imaging agents
delivered prior to surgery can provide unique information about
the tumor susceptibility to certain targeted drugs, susceptibility
to systemically delivered agents, and appropriate therapeutic
agent dosing. As the agent would be delivered prior to surgical
removal, the tissue would be available for molecular, genomic,
and histological examination.
The other major opportunity has been the creative growth in
molecular probes for surgical guidance. A listing of those
registered with clinicaltrials.org for patient recruitment is
shown below in Table 2, illustrating the wide diversity of probes
being tested, with a range of more and more specific binding
Table 1 A SWOT analysis of the field for clinical molecular guided surgery.
Strengths Weaknesses
• Robust commercial production of fluorescence guidance
surgical/laparoscopy systems
• Mismatch between imaging tools today and ability to see/use
biochemical heterogeneity
• Phase 0/1 trials occurring • Over-reliance on preclinical tumors that are specifically chosen as
highly positive
• First FDA approval for a biosynthetic-activated molecular surgical
probe has occurred in 2017 and is being widely adopted
• Variability in clinical trial data reporting and target validation
• Lack of standardization in analyses
• Regulatory processes not optimally designed to assess
low-dose/near-microdose agents for molecular imaging or
multiple probes at one time
Opportunities Threats
• Well-developed molecular pathology tools to phenotype biopsy
tissue prior to surgery
• Misinterpretation of in vivo data, confusing uptake for
molecular-specific uptake and how it is reported
• Proven molecular probes (metabolism, immunology, and mRNA) • Production and toxicity tests require lower cost approaches
• Potential to save surgical time or make resection better match
presurgical images
• Surgical trials inherently difficult to run due to variations between
surgeons, institutional norms, and pathology processing
• Recognize close or positive margins in real-time during surgery
• New strategies for time consuming procedures such as sentinel
node mapping
• Reimbursement for intraoperative imaging not established
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Table 2 Listing of fluorescence guided surgery procedures and probes listed in clinicaltrials.gov.
Type of molecular probe Molecule/probe Commercial name Clinical site or purpose (registered at www.clinicaltrials.gov)
Vascular
perfusion/flow
Indocyanine green ICG, AIM ICG Many organ/tissue sites (>400 trials)
Lymphatic
flow/sentinel nodes
tissue retention
Indocyanine green ICG Breast, parathyroid, tumors (>40 trials)
Methylene blue MB-102
Autofluorescence NADH/FAD n/a Many organ/tissue sites (>190 trials)
DNA intercalation Proflavine n/a Squamous cell neoplasia, Barrett’s esophagus, colon polyps,
dysplasia, anal dysplasia, head and neck cancer, cervix
cancer, uterine cancer, oral disorders, gastric cancer (17 trials)
Molecular vibrations Raman scattering n/a Liver, macula, foot ulcers, glucose (>100 trials)
Metabolism—enzyme
or synthetic activity
ALA Gliolan Glioma, bladder (13 trials)
Levulan Skin precancers and cancers (>200 mostly PDT trials)
NPC-07 Glioma (one trial)
Hexaminolevulinate Cysview Bladder, cervix, colorectal cancer (four trials)
Methyl aminolevulinate Metvixia Skin AKs, cancers, Bowen’s disease, acne (68 mostly PDT trials)
Cathepsin activatable LUM015 Sarcoma, colorectal, pancreatic esophageal, breast,
prostate cancers (five trials)
Protease activatable AVB-620 Breast cancer (two trials)
Metabolism—
carbohydrates
and proteins
Fluorescent lectin n/a Colorectal cancer, neoplasms, polyps (one trial)
HSP90 inhibitor HS-196 Solid tumors (one trial)
Chlorotoxin blocking
chloride channels
with Cy5.5
BLZ-100 glioma, breast, CNS, skin, sarcoma (five trials)
7-aa peptide—
IRDye800CW
KSP-910638G
heptapeptide
Gastrointestinal malignancies
c-Met targeting peptide EMI-137 Colon cancer, esophageal cancer and high grade dysplasia,
papillary thyroid cancer, lung cancer (four trials)
Immunology—receptor
and cell surface
protein targeting
Folate receptor targeting OTL38 Renal cell, lung, ovarian, pituitary, pleural cancers (nine trials)
Tumor-specific integrin
receptor binding
LS301 Breast cancer (one trial)
Anti-EGFR binding peptide QRH-882260 Colon cancer, cholangiocarcinoma (three trials)
Anti-EGFR affibody ABY-029 Glioma, sarcoma, head, and neck (three trials)
GRPR receptor
binding peptide
68GA-BBN-
IRDye800CW
Glioblastoma (two trials)
VEGF antibody Bevacizumab-
IRDye800CW
Esophageal, breast cancer, adenomatous polyposis (nine trials)
EGFR antibody Cetuximab-
IRDye800CW
Pancreatic cancer, brain neoplasms, glioma, head and neck
squamous cell carcinoma, head and neck cancer (four trials)
EGFR antibody Panitumumab-
IRDye800
Pancreatic cancer, brain neoplasms, glioma, head and neck
squamous cell carcinoma, head and neck cancer (four trials)
Carbonic anhydrase IX
antibody
111In-DOTA-
Girentuximab-
IRDye800CW
Renal cell carcinoma (one trial)
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characteristics, ranging from endogenous molecules in the
beginning to exogenous probes that specially bind to cell
surface carbohydrates, free proteins, specific enzymes, cellular
channels, or cell surface receptors. The specificity of each is
known a priori, and the efficacy in vivo is being tested in
these early phase trials. At this point, most of the more specific
agents have not advanced beyond Phase 1 trial, but there is
potential. However, some of the factors listed next will deter-
mine success or failure of these trials.
The weaknesses of the field are the issues that will limit the
successes if not solved. One of the most obvious and yet least
discussed aspects of the field is that molecular-specific dyes
have a localization that is often microscopically heterogeneous,
and so this is not easily appreciated with surgical imaging
in vivo. Although bulk tissue removal can still aid the surgeon
as guided by the fluorescence signal, there are diseases, such
as brain or ovarian cancer, where microscopic pathology
removal is more critical and macroscopic views of the
fluorescence will be insufficient. Pathology analysis of immu-
nohistochemistry slides routinely shows high morphological
heterogeneity in tumor nodules and ducts, indicating that spe-
cific molecular probes to these targets would likely also be
microscopically heterogeneous. A pathologist is trained to
view this heterogeneity and make sense of it, knowing that stain-
ing patterns are usually complex, and it is this complexity that
can be one of the keys to diagnosis. Yet a surgeon must perform
resection at the macroscopic or perhaps mesoscopic resolution.
The macroscopic view of a heterogeneous uptake blurs out the
uptake and observed contrast, and so in vivo levels of tumor to
background are routinely seen near 1.1× to 5×.35,36 Whereas if
the view was at the cellular or near cellular level, contrast
appears at much higher levels, nearer 10× to 30× is common,
but this cannot be resolved when imaging at the macroscopic
scale (see examples from three different molecular tracers in
Fig. 1). The difficulty lies in the basic fact that most surgical
procedures perform random sampling of the tumor at the micro-
scopic level through use of frozen sections, but do not allow for
thorough microscopic examination of the tissue, and the accom-
panying microscopic-level image extraction. The surgeon, in
general, is interested in the margin and not the complete volume
of the tumor, even with all its heterogeneous components. It is
the microscopic margin and the interaction with the micro-
environment that presents the leading challenge to the surgeon
toward macroscopic imaging. So, the field is left with a situation
where the technological imaging tools used will not allow
for imaging of the true disease-specific morphology, which
might be better used. Perhaps even worse is the fact that as
this is seemingly unrealizable, most of the focus of the field is
on quantifying the available modest contrast and making deci-
sions based upon this rather poor reporter of the true molecular
specificity.40 An interesting side aspect of this though is that this
problem is an issue for nuclear medicine molecular imaging
as well as fluorescence-guided surgery (FGS), as macroscopic
imaging resolution simply does not allow for delineation of
the microscopic phenotypic heterogeneity of cancer, whereas in
standard-of-care one might challenge if this is a real problem in
the surgical theatre.
One solution to imaging of the cancer heterogeneity issues, is
to have a combination of: (1) a widefield high-resolution imag-
ing system and (2) an automated software to recognize and clas-
sify the molecular morphology patterns. This would be similar
to what is seen in immunohistochemistry, and automation of this
is coming, but for now it remains one of the key weaknesses of
the field, where the observed contrast levels seen are distinctly
unimpressive. Alternatively, it is possible that fast magnification
change imaging could be possible where the low power, low
magnification can be quickly swept up to higher power and
high resolution. The value of this is that the scoping in and
out from macroscopic to microscopic imaging would allow
for superior workflow for the surgeon, who desires the ability
to see boundaries or fine structures better. Without these types of
tools, many companies developing molecular probes may fail to
see the high contrast in vivo, ignoring the tumor specificity it
delivers in ex vivo analyses. As such, they might see a mismatch
between in vivo and in vitro data and stop development of new
molecular probes. So, while this problem can seem trivial, with-
out a technological or logistical solution to it, there will remain a
lack of clarity in target validation. What remains pivotal is com-
paring imaging data with the accepted gold standard in daily
clinical care, which remains simple H/E histopathology. One
practical issue is the comparison of frozen section fluorescence
imaging to fixed H&E pathology images, which requires chal-
lenging and labor-intensive comparison studies.35,41,42 This is
done because many targeted probes do not remain intact or
active when fixed, although there are some which appear to
have this characteristic. This seemingly trivial issue is a major
challenge though to target verification with in vivo–ex vivo
assay. Efforts to apply deep learning systems comparing in vivo
fluorescence with ex vivo tumor delineation might be a solution
in this complex equation. This is an important part of clinical
trial testing, which without an appreciation for it could lead
to a slowing of enthusiasm because of a perceived low contrast,
stymying research and development in this field.
Another major weakness of the field, which pervades all of
molecular cancer research, is the over-reliance of preclinical
testing in tumor cell lines that are monolithically positive for
the molecular target of interest.43,44 For example, if a single
receptor directed probe is being tested, then it is tested on
a tumor line that has exceptionally high expression of that recep-
tor, because it needs to be shown that it has specificity. However,
when deployed in humans, the tumor heterogeneity in terms of
any protein expression can range by orders of magnitude. This
preclinical approach is done for practical and economic reasons,
and even though it is a widely recognized problem in cancer
research, and publishers and funding agencies are trying to mit-
igate it, there are few obvious practical solutions.45 The cost of
preclinical work is high, and the complexity of trying to test
a molecular probe in hundreds of tumor models in vivo is
implausible, although some methods are being proposed now.46
Yet, as soon as the same molecular probe is used in human
trials, the range of tumors imaged can be enormously more
variable than the singular xenograft models that were tested on.
Additionally, the size and growth of the human tumor can alter
the value of targeting, as it is well known that as tumors grow,
the phenotypic characteristics can vary throughout the tumor,
with variations in gene expression, protein expression, and
mutated protein expression.
Given this, the ability to know the expression level and the
heterogeneity of expression may be the key to allowing success
in use of the molecular probe.43 A concern is the use of targeted
fluorescence imaging in a clinical trial, often consisting of
a heterogeneous patient population in terms of age, sex, tumor
size, tumor heterogeneity, neoadjuvant treatment, comorbidities,
etc., which might have results that are confounded by uncertain
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or inconclusive data about the observed target contrast, without
better interpretation of both the expression and microscopic
heterogeneity of this expression. Mitigating this problem
could come at both ends of the pipeline, in terms of using
more tumor lines in three-dimensional (3-D) culture or premade
arrays, and then also better appreciating the in vivo pathology
of each individual patient being imaged.47 Measurements of
molecular probes though are limited to a static IHC expression,
Fig. 1 Differences in bulk contrast versus high microscopic contrast are shown. Bulk tissue imaging of
NIR fluorescence image from LS30137 (a) overlaid on white light image of a mouse tumor, showing
a fluorescence to background signal ratio, reported as 1.2 across mice. (b) High-resolution fluorescence
microscopy shows colocalization (yellow) of iRFP signal (green) and LS301 fluorescence (red) exhibiting
the expected high microscopic heterogeneity of the cancer. (c) Histological confirmation of the same slide
showing cancerous growth corresponding to the areas marked by iRFP and LS301 fluorescence.
Visualization of a tumor from trastuzumab-IRDye800CW,38 with a color white-light images (a), fluores-
cence (e) and overlay fluorescence of the two (f), with a reported tumor to background ratio of 2.7.
The H&E stained tissue slides (g) and (h) show the subcutaneous tumor microscopy with heterogeneity
on the 10’s of microns spatial scale, [scale bars 1 mm (g) and 50 μm (h)]. Fluorescent images of
cetuximab-IRDye800CW39 are shown in serially cut fresh tumor (i) for different weights with a subsequent
reduced TBR at each size, relative to normal tissue. The histological image and from H&E (j) and
EGFR (k) are shown with the ex vivo fluorescent images (l) of a representative section showing the
microscopic heterogeneity present in the tumor, and high labeling contrast.
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and this expression could vary over time and with sample han-
dling. Target expression that is expressed at a low level but inter-
nalizes quickly may produce a much better signal. Furthermore,
establishment of the need to identify the marker on every patient
will make the process more expensive and invasive (especially,
in sites like brain tumors where biopsies are rarely performed).
In the end, the only current plausible solution is that the probe
validation needs to be performed postsurgery by assessment of
the histology/fluorescence.
Another weakness of the field is the regulatory processes that
limit development and deployment of imaging probes to one at
a time, with good manufacturing practices (GMP) production
requirements, release testing, toxicity testing, and ongoing
stability analysis for each molecule.4 It is possible that optimal
tissue selectivity may require the type of combination targeted
which is common place in clinical oncology today. This could
take advantage of multiple epitopes, multiple receptors, and nor-
mal and mutated proteins, protein–carbohydrate combinations,
multiple enzymes, or combinations of metabolism and immune
profiles if tissue. However, the commercial barriers to imaging
agents are significant,48,49 and even getting a single agent into
approved/cleared use today seems nearly insurmountable.
Thus, without a different strategy, multiple targeting moieties
are unlikely to be commercially plausible. In fact, the codevel-
opment of a therapeutic and diagnostic agent is a conflict of
interest as the returns are so lopsided; industry is often unwilling
to tolerate the risk of the therapeutic agent.
The threats to FGS are perhaps the most troubling and
require some careful thought before they derail progress in
the field. Although each threat may not have immediate solu-
tions, it is critical to appreciate them. The largest and most press-
ing threat is the fact that clinically observed contrast and uptake
data are being misinterpreted at times in terms of the specificity
of the signal. As previously mentioned in the weakness area,
limitations of current macroscopic imaging systems can be
a problem that leads to an underestimation of the specificity
for the molecular probe to the target. But an even further prob-
lem that is more insidious is that macroscopic imaging tools
simply cannot provide verified information about the specificity
of uptake. It is very common for researchers to interpret the
macroscopic contrast as the specificity of probe, and yet, factors
such as vascular perfusion and lymphatic impairment can often
have more effect upon the uptake than any specificity of binding
or localization. This is well known as the enhanced permeability
and retention (EPR) effect,50 and yet it is also commonly ignored
when interpreting preclinical data and clinical data. This is
avoided often for the simple reason that the macroscopic imag-
ing tool cannot resolve the uptake and that the uptake patterns
are mixed in with vascular perfusion patterns. Although addi-
tional target validation at the microscopic level is possible,
it requires additional effort and is not always recognized by
people in the development pipeline as a necessary step in the
process of agent development. As a result, parsing out the
vascular, localization, and lymphatic effects can be scientifically
challenging and expensive to do well (Fig. 2).
It is very common to simply compare two tumor lines,
one positive for the target, and one negative for the target as
a quantitative assay of specificity of uptake. Yet, while this
seems reasonable, these two tumor lines can easily have much
larger vascular perfusion and lymphatic flow differences, which
will dwarf the effects of the probe binding. Preclinical testing of
specificity in this manner, while seemingly logical, based just on
the target, adds a high level of randomness to the field, and many
published studies have data that are confounded by this issue.
Solutions to this problem are complex and require more careful
microscopic and pathologic analysis of uptake, comparing
matched targeted and untargeted probes, to ensure that the
measured bulk uptake is actually bound to the target or activated
by the expected target. Solutions such as using a reference tissue
to normalize are insufficient,51 because they do not solve the
problem of the specificity of uptake. Modeling studies,52,53,54
detailed immunohistochemistry studies, or comparison with
Fig. 2 Example of microscopic target validation: panitumumab-IRDye800 localizing in head and neck
squamous cell carcinoma (yellow line) but not in surrounding stromal and inflammatory tissues. This
represents positive target validation but does not rule out off-target effects or failure to target all elements
of cancer distributed throughout the tumor mass.
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a paired tracer can each potentially mitigate the problem,55,56 but
are more easily implemented at the preclinical stage than the
clinical stage.
Another key threat is the lack of an obvious way to advance
production and in vivo toxicity testing in a way that allows the
cost to match the benefit.48,49 The hardest part of this as the field
evolves is having examples of business cases that allow for com-
panies to recoup their expenditures for the development cost.
Current GMP (cGMP) production of small organic dyes for
human use have been pioneered by a few groups, such as the
work of Hyun and colleagues.57 Conventional contrast agents
have been reducing in numbers for most of the last decade,58
and the development of new CTandMRI contrast agents is com-
paratively stagnant, and this is even true in nuclear medicine.
This is related to a lack of additive potential revenue from
their use. This is a challenging problem, although solutions
may exist in following a few of the case examples in nuclear
medicine,2 taking advantage of the use of cGMP methods in
academic laboratories with initial human testing in microdose
trials.59,60 Perhaps the most common method of using this
research-based approach, especially when there is limited return
but high value to the patient, is the development of registries
supported by the Centers for Medicare and Medicaid
Services. This method was critically successful in molecular im-
aging, providing for the development of FDG-PET imaging, and
seems a viable pathway, as long as the imaging systems used are
sufficiently sensitive enough to image nanomolar levels of
agent.29,60,61,62 Other solutions may also emerge as the field
develops, such as gaining approvals for mixtures of agents at
a time, although this is seemingly harder to imagine as time
goes on.
Toxicity and release testing will always be a necessary and
expensive part of the process as well, which cannot be avoided.
However, there are methods that can limit costs, if, for example,
the imaging is done with therapeutic proteins that have already
undergone substantial human use, and can be slightly modified
without altering their pharmacokinetic behavior. In these
cases, minimal testing might be feasible under negotiation with
regulatory bodies.4 Alternatively, microdose studies are also
possible,59,60,63 which reduce the required toxicity studies to a
single rodent species with a single injection, from the more com-
plex multiple-species-multiple-dose studies. This can be effec-
tively completed for a modest cost and can even be completed
on the test batch of an agent instead of the final product, as long
as there is consistent good laboratory practice followed between
the production stages. Toxicity testing will become a larger
aspect of agents as they expand and while this is not a biomedi-
cal optics problem per se, there are approaches such as in vivo
pharmacokinetic imaging,64 which might be deployed to reduce
animal use and cost. Similarly, in vivo optical imaging to assess
activity and target bioavailability will likely be useful to confirm
the value of agents.65 Finally, better understanding of the in vivo
kinetics and clearance organ behavior of both the dye and the
targeting moiety can alleviate some of the costs of preclinical
work,66,67 where some are developed without sufficient planning
for avoiding organs at risk or appropriate clearance kinetics.
The threat about economic viability for new molecular
probes is less of an issue for small molecules than it is for larger
biological agents, and it is likely that the two will have very
different development paths. It is possible that once the safety
of fluorescently labeled therapeutic antibodies has been better
established, one could make the case that small labeling changes
are relatively minor, and that these agents, if made under certain
parameters, should inherently have FDA clearance if the anti-
bodies are already in common human use.4 This is valid if
the fluorescent labeled antibody has the same biological clear-
ance and activity as the native antibody, because with careful
labeling there is minimal effect to a 155-kDa antibody from
a 0.5-kDa dye added to it. This has been done by several groups
in ongoing clinical trials in the US, with Cetuximab and
Panitumumab,68,69 and in Europe, with bevacizumab and an
anti-CEA antibody.70 The application of this approach to devel-
oping agents for multicenter clinical trials has not been achieved
yet, nor to FDA cleared products, but it is a promising pathway.
Summary
The perceived value of molecular guided surgery is exception-
ally high. It comes with the promise of combining molecular
pathology information into a nuclear medicine-like molecular
guidance, which would improve the precision of surgical
procedures. Increasing interest by different surgical specialties
has been robust,3 matching the commercial investment occur-
ring. To keep this field progressing to its highest potential,
the issues mentioned in the weaknesses and threats areas
need attention and creative input from partners in engineering,
medicine, and industry.
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